Hentzien et al., Validation of the Dat’AIDS score in the SHCS
External validation of the Dat’AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.  HIV Medicine Hentzien et al. aimed to externally validate the Dat’AIDS score’s capacity to predict 5-yearoverall mortality in people with HIV (PWH) aged 60 or older, using data from the […]
Jörimann et al., No evolution on dolutegravir monotherapy
Absence of HIV-1 evolution in early-treated individuals with HIV switching to dolutegravir monotherapy during 48 weeks.  The Journal of Infectious Diseases Jörimann et al. evaluated the impact of dolutegravir (DTG) monotherapy on the dynamics and the evolution of the viral reservoir among people with acute HIV infection. Specifically, the authors tested the hypothesis of ongoing […]
Labarile et al. Quantifying HIV-1 transmission dynamics
Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approach.  The Journal of Infectious Diseases Labarile et al. aimed to analyze cluster growth dynamics in the Swiss HIV epidemic in the context of the Swiss HIV Cohort Study (SHCS) as well as the predictive capabilities […]
Tepekule et al., Impatto della tubercolosi latente sul diabete mellito
Impatto della tubercolosi latente sul diabete mellito.  Journal of Infectious Diseases Nella maggioranza dei casi le infezioni da micobatteri della tubercolosi sono latenti, ciò significa che sono controllate dal sistema immunitario e che non causano un’infezione manifesta. Ricerche precedenti condotte nell’ambito dello Studio Svizzero della Cohorte HIV (SHCS) hanno mostrato che le persone con tubercolosi latente […]
Tepekule et al., Auswirkungen der latenten Tuberkuloseinfektionen auf Diabetes mellitus
Auswirkungen der latenten Tuberkuloseinfektionen auf Diabetes mellitus.  Journal of Infectious Diseases Tuberkuloseinfektionen verlaufen in den meisten Fällen latent, was bedeutet, dass sie vom Immunsystem kontrolliert werden und nicht zu einer aktiven Erkrankung führen. Frühere Forschungsarbeiten der Schweizerischen HIV-Kohortenstudie (SHCS) konnten zeigen, dass Personen mit einer latenten Tuberkuloseinfektion seltener an Infektionen im Zusammenhang mit HIV […]
Tepekule et al., Impact des infections tuberculeuses latentes sur le diabète sucré
Impact des infections tuberculeuses latentes sur le diabète sucré. Journal of Infectious Diseases Dans la plupart des cas, les infections tuberculeuses sont latentes, ce qui signifie qu’elles sont contrôlées par le système immunitaire et n’entraînent pas de maladie active. Des recherches antérieures menées dans le cadre de l’Etude suisse de cohorte VIH (SHCS) ont montré […]
Trickey et al., Life expectancy of adults with HIV on long-term ART
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV Trickey et al. estimated the life expectancy of people with HIV (PWH) who received suppressive antiretroviral therapy (ART) after 2015, when treatment guidelines started to recommend ART for all PWH […]
Berton et al., Exposure and response of antiretrovirals in obese PWH
Antiretroviral drug exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data.  Clinical Infectious Disease. Berton et al. aimed to perform virtual trials using physiologically based pharmacokinetic (PBPK) modelling combined with therapeutic drug monitoring (TDM) data and the corresponding viral load data obtained from […]
Jaha and Schenkel et al., Prevalence of HIV-1 drug resistance mutations in proviral DNA
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.  Journal of Antimicrobial Chemotherapy Jaha and Schenkel et al. developed a protocol to perform proviral DNA genotypic resistance testing and evaluated the prevalence of drug resistance mutations (DRM) among people with HIV in […]
Neesgaard et al., Inibitori dell’integrasi e malattie cardiovascolari
Associazione tra inibitori dell’integrasi e malattie cardiovascolari nelle persone che vivono con l’HIV: uno studio prospettico multicentrico del consorzio di coorti RESPOND.  Lancet HIV Le malattie cardiovascolari sono fonte di preoccupazione nella presa in carico delle persone che vivono con l’HIV (PVHIV). In effetti da quando vi è un accesso universale al trattamento antiretrovirale, l’aspettativa […]